相关实验视频

Updated: Jun 18, 2025

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

11.9K

单臂,首次在人体上的可行性研究结果为超低成本的胰岛素

Matthew Payne1, Francis Pooke2, Tom M Wilkinson3

  • 1Department of Mechanical Engineering, Centre for Bioengineering, University of Canterbury, 20 Kirkwood Avenue, Christchurch, 8041, New Zealand. matt.payne@pg.canterbury.ac.nz.

BMC endocrine disorders
|August 1, 2024
PubMed
概括

一个开源的,超低成本的胰岛素 (ULCIP) 在首次针对1型糖尿病 (T1D) 的人体试验中证明了安全的胰岛素输送. 这种负担得起的设备有望改善胰岛素治疗的可获得性.

关键词:
临床试验临床试验是指临床试验的临床试验.胰岛素可以提供胰岛素.低成本的低成本的成本.这是开源的,开源的.

更多相关视频

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

1.8K
Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol08:04

Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol

Published on: November 3, 2023

1.9K

相关概念视频

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
163